Clinical trial
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on…
NCT00294723 · Novo Nordisk A/S, Industry · Terminated
Key facts
| NCT number | NCT00294723 |
|---|---|
| Title | To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c |
| Official title | Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes |
| Acronym | LEAD-3 |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | liraglutide, glimepiride, placebo |
| Enrollment | 746 |
| Start date | Feb 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Feb 22, 2006 |
| Last update posted | Mar 7, 2017 |
| Countries | Mexico, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: